Related Experiment Video
Updated: Dec 13, 2025
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
Rare Cases of IDH1 Mutations in Spinal Cord Astrocytomas
N A Konovalov1, D S Asyutin1, E G Shayhaev2
1National Medical Research Center of Neurosurgery, Ministry of Health of the Russian Federation Acad. N.N. Burdenko, Moscow, 125047 Russia.
Abstract:
A low occurrence rate of spinal cord gliomas (4.3% of primary and glial CNS tumors) and the associated difficulties in building statistically significant cohorts of patients considerably slow down the development of effective approaches to the treatment of spinal cord tumors compared to brain tumors. Despite our extensive knowledge regarding IDH mutations in intracranial tumors, mutations of this gene in spinal cord astrocytomas remain poorly understood. In this study, we report on five cases of identified mutations in the IDH1 gene in spinal cord astrocytoma cells, two of which are unique, as they have never been previously described in CNS gliomas.
Insights
Spinal cord astrocytomas show low IDH1 gene mutation rates. This study identifies five IDH1 mutations, including two novel mutations, in spinal cord astrocytoma cells, advancing understanding of these rare tumors.
Area of Science:
- Neuro-oncology
- Molecular genetics
- Cancer research
Background:
- Spinal cord gliomas are rare, hindering treatment development compared to brain tumors.
- IDH gene mutations are well-studied in brain gliomas but poorly understood in spinal cord astrocytomas.
Purpose of the Study:
- To investigate the role and frequency of IDH1 gene mutations in spinal cord astrocytomas.
- To identify and characterize novel IDH1 mutations in this rare tumor type.
Main Methods:
- Analysis of patient samples with spinal cord astrocytoma.
- Genetic sequencing to identify mutations in the IDH1 gene.
Main Results:
- Identified mutations in the IDH1 gene in five cases of spinal cord astrocytoma.
- Discovered two unique IDH1 mutations not previously reported in central nervous system (CNS) gliomas.
Conclusions:
- This study expands the known spectrum of IDH1 mutations in CNS gliomas.
- Findings contribute to a better understanding of the molecular landscape of spinal cord astrocytomas, potentially informing future therapeutic strategies.
